Antibodies, Neoplasm
"Antibodies, Neoplasm" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Immunoglobulins induced by antigens specific for tumors other than the normally occurring HISTOCOMPATIBILITY ANTIGENS.
Descriptor ID |
D000912
|
MeSH Number(s) |
D12.776.124.486.485.114.240 D12.776.124.790.651.114.240 D12.776.377.715.548.114.240
|
Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Antibodies, Neoplasm".
Below are MeSH descriptors whose meaning is more specific than "Antibodies, Neoplasm".
This graph shows the total number of publications written about "Antibodies, Neoplasm" by people in this website by year, and whether "Antibodies, Neoplasm" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
Year | Major Topic | Minor Topic | Total |
---|
1994 | 1 | 0 | 1 | 2001 | 1 | 0 | 1 | 2004 | 0 | 1 | 1 | 2005 | 0 | 1 | 1 | 2006 | 1 | 0 | 1 | 2007 | 3 | 2 | 5 | 2008 | 0 | 1 | 1 | 2009 | 1 | 1 | 2 | 2012 | 2 | 0 | 2 | 2015 | 0 | 1 | 1 | 2016 | 1 | 0 | 1 | 2017 | 1 | 0 | 1 | 2018 | 0 | 1 | 1 | 2021 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Antibodies, Neoplasm" by people in Profiles.
-
Rawat K, Tewari A, Morrisson MJ, Wager TD, Jakubzick CV. Redefining innate natural antibodies as important contributors to anti-tumor immunity. Elife. 2021 10 05; 10.
-
Su Y, Liu Y, Behrens CR, Bidlingmaier S, Lee NK, Aggarwal R, Sherbenou DW, Burlingame AL, Hann BC, Simko JP, Premasekharan G, Paris PL, Shuman MA, Seo Y, Small EJ, Liu B. Targeting CD46 for both adenocarcinoma and neuroendocrine prostate cancer. JCI Insight. 2018 09 06; 3(17).
-
Dourado KMC, Baik J, Oliveira VKP, Beltrame M, Yamamoto A, Theuer CP, Figueiredo CAV, Verneris MR, Perlingeiro RCR. Endoglin: a novel target for therapeutic intervention in acute leukemias revealed in xenograft mouse models. Blood. 2017 05 04; 129(18):2526-2536.
-
Sherbenou DW, Aftab BT, Su Y, Behrens CR, Wiita A, Logan AC, Acosta-Alvear D, Hann BC, Walter P, Shuman MA, Wu X, Atkinson JP, Wolf JL, Martin TG, Liu B. Antibody-drug conjugate targeting CD46 eliminates multiple myeloma cells. J Clin Invest. 2016 12 01; 126(12):4640-4653.
-
Diamond JR, Wu B, Agarwal N, Bowles DW, Lam ET, Werner TL, Rasmussen E, Gamelin E, Soto F, Friberg G, Sun YN, Sharma S. Pharmacokinetic drug-drug interaction study of the angiopoietin-1/angiopoietin-2-inhibiting peptibody trebananib (AMG 386) and paclitaxel in patients with advanced solid tumors. Invest New Drugs. 2015 Jun; 33(3):691-9.
-
Arruda DC, Santos LC, Melo FM, Pereira FV, Figueiredo CR, Matsuo AL, Mortara RA, Juliano MA, Rodrigues EG, Dobroff AS, Polonelli L, Travassos LR. ?-Actin-binding complementarity-determining region 2 of variable heavy chain from monoclonal antibody C7 induces apoptosis in several human tumor cells and is protective against metastatic melanoma. J Biol Chem. 2012 Apr 27; 287(18):14912-22.
-
Qamar L, Deitsch E, Patrick AN, Post MD, Spillman MA, Iwanaga R, Thorburn A, Ford HL, Behbakht K. Specificity and prognostic validation of a polyclonal antibody to detect Six1 homeoprotein in ovarian cancer. Gynecol Oncol. 2012 May; 125(2):451-7.
-
Dietz AC, Orchard PJ, Baker KS, Giller RH, Savage SA, Alter BP, Tolar J. Disease-specific hematopoietic cell transplantation: nonmyeloablative conditioning regimen for dyskeratosis congenita. Bone Marrow Transplant. 2011 Jan; 46(1):98-104.
-
Dalakas MC, Rakocevic G, Schmidt J, Salajegheh M, McElroy B, Harris-Love MO, Shrader JA, Levy EW, Dambrosia J, Kampen RL, Bruno DA, Kirk AD. Effect of Alemtuzumab (CAMPATH 1-H) in patients with inclusion-body myositis. Brain. 2009 Jun; 132(Pt 6):1536-44.
-
Birks DK, Kleinschmidt-DeMasters BK, Donson AM, Barton VN, McNatt SA, Foreman NK, Handler MH. Claudin 6 is a positive marker for atypical teratoid/rhabdoid tumors. Brain Pathol. 2010 Jan; 20(1):140-50.
|
People People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|